Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Your Article Summary
See Latest ArticlesA case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden
The European Journal of Health Economics, 08/04/09
Persson U et al. – Ex ante VBP assessment is a form of risk sharing, which has been used by TLV to speed up reimbursement and dispersion of effective new drugs despite uncertainty in their true cost–effectiveness. Manufacturers are often asked in return to generate additional health economic evidence that will establish cost–effectiveness as part of ex post review. The alternative is to delay the reimbursement approval until satisfactory evidence is available.
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Medicare cracks down on false claims
Medical Economics, 11/02/09
2009 earnings survey: How do you compare
Medical Economics, 09/29/09
How sensitive is physician performance to alternative compensation schedules? Evidence from a large network of primary care clinics
Health Economics, 10/29/09
Sponsor
Article Search
Sponsor